Carlos Gomez‐Roca

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial

Jean‐Sébastien Frenel, Christophe Le Tourneau, Bert H. O’Neil et al. · Journal of Clinical Oncology · 2017 · 522 citations

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

Céline Berthon, Emmanuel Raffoux, Xavier Thomas et al. · The Lancet Haematology · 2016 · 425 citations

Hematological Malignancy, Translational Medicine, Acute Leukaemia +14

Clinical Response of Carcinomas Harboring the BRD4–NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628

Anastasios Stathis, Emanuele Zucca, Mohamed Békradda et al. · Cancer Discovery · 2016 · 371 citations · Full text

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

Bert H. O’Neil, John M. Wallmark, David Lorente et al. · PLoS ONE · 2017 · 299 citations · Full text

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

Patrick A. Ott, Sarina A. Piha‐Paul, Pamela N. Münster et al. · Annals of Oncology · 2017 · 250 citations · Full text